Tonix Pharmaceuticals Holding Corporation (TNXP) News

$TNXP Not sure if this was posted earlier. https://www.benzinga.com/content/43398091/is-tonix-pharmaceuticals-the-next-biotech-breakout

Per the website finance.yahoo.com, this Diamond-In-Rough has $57.61 per share Huge Book Value which is very close to its Analyst's Average Target Price $53.50 (the High Target is $96 while the Low Target is $11)!

So, the Daily Highs area $1.94 ~ $1.30 (on 12/17/2024) are still Too Low comparing to either its Huge Book Value or its Huge Target Price Levels!

The next Key technical resistance is the 200-Day MAL is $1.342 which is in between 12/17/24's Daily Highs area $1.94 ~ $1.30!

TNXP has "BULLISH" ratings from various stock-rating websites!

Huge trading price Gaps between $5.0 and $1.30 from the second chart below will be filled up before the FDA-Approval Day 08/15/2025...

It could be. The share price as mentioned yesterday got 'happy'
as it 'found' its moving average line. And then today, completed
the 'touch and go' by bouncing off it nicely.

So as of tonight? The MA has a positive slope to it, ready to
try and help 'guide' the share price higher.

And a buy signal I use remains 'closed'

So agree, based on my chart tonight, have to say TNXP
closed out the week on a positive 'note'

next week will be interesting. IMO

$TNXP https://www.tonixpharma.com/ Any New Updates / News Could Come Out Anytime!

CORRECTION;
Jjefferies analyst expects about $80 million in added revenue,
$7 billion increase in market value based on $80 million revenue.
This makes the computation I provided based on $1 billion revenue overly conservative.
Multiply impact on tnxp market valuation by 12x
In the example, Using the same ratio.

SMH! Why do you feel the need to advertise this?

goal date is august that is not new will hit anytime now lol

Another successful flip for me today. Bought low 40 and sold at 43. Profit is profit. It's Friday. I knew was going no where

$TNXP The Company provided updated guidance on the timing of topline data for two of its programs: topline data for the Phase 2 study of the Company’s TNX-1300 product candidate for cocaine intoxication is expected in the third quarter of 2025; and topline data for the Phase 1 study of the Company’s TNX-1500 product candidate for the prevention of kidney transplant rejection is expected in the first quarter of 2025.

That new approval I wrote about late yesterday, so far added $7 billions in market value & it’s based on a potential revenue of $1 billion.
Think what will FDA approval mean to tnxp market value!
Will it be $1 billion valuation increase, based on potential revenue of $143 millions!
I used the same ratio as above 7 to 1 ratio.
Share price based on this would reach $6
No doubt revenue will be much more than $143 millions.
Revenue can be as much as $1 billion/year.
Hopefully this is not too confusing to some!
If you think the potential revenue is more than $143 millions, figure out your resulting share price.
Potential Share price,
(Revenue/143)x6 = ?
($1B/143M)x6 = $42
August & beyond ⬆️

Any New News could hit anytime Now! A reminder of Jan 8, 2025 Press release!

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

Mr. Ainsworth brings over two decades of industry and market access experience to Tonix

U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for U.S. marketing authorization of TNX-102 SL for the management of fibromyalgia

CHATHAM, N.J., January 8, 2025 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the appointment of Gary Ainsworth as Vice President, Market Access, effective immediately. Mr. Ainsworth is an accomplished executive with leadership in market access strategies from both large pharmaceutical companies and healthcare consultancies.

“Gary has a significant track record of success building market access functions, developing launch-ready access and reimbursement strategies and payer-focused resources, including those for fibromyalgia and migraine treatment options,” said Thomas Englese, EVP Commercial of Tonix Pharmaceuticals. “His extensive experience will be especially valuable as we work towards the potential approval and commercial launch of TNX-102 SL for the management of fibromyalgia this year.”

Most recently, Mr. Ainsworth was Managing Director, Head of Market Access at Eversana Intouch, where he led the agency function and the efforts to optimize the Company’s vast market access capabilities and services. Prior to that, he was the founder and Managing Director at Havas Gemini, the Market Access Business Unit of Havas Health & You that developed innovative market access strategies and solutions for their clients. Mr. Ainsworth also had a distinguished career leading pharmaceutical organizations’ market access functions. Mr. Ainsworth was the Vice President of Corporate Accounts and Customer Operations for Baxter International within the Anesthesia, Critical Care and Oncology Division where he led a team of national account managers and a patient services telemarketing center. Mr. Ainsworth also led the National Accounts and Managed Care Marketing function at Roche Laboratories and held a variety of market access leadership positions with the predecessor companies to Sanofi. Mr. Ainsworth holds a Master of Business Administration from Rockhurst University and a Bachelor of Arts in Business Administration and a Bachelor of Arts in Public Relations from William Jewell College.

“Joining the Tonix team presents an exciting and fulfilling opportunity to help advance a treatment for the millions of individuals with fibromyalgia,” said Mr. Ainsworth. “I look forward to providing additional expertise to a seasoned leadership team with the goal of bringing meaningful therapeutics to patients in need.”

At the end of December 2024, Tonix announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing authorization for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia. TNX-102 SL is a non-opioid, centrally-acting analgesic. Fibromyalgia is a common chronic pain condition that affects mostly women.

Congratulations!
You just became a Ihub member today!
This is your first post!
You picked this question in your first post!

Good Luck!
$TNXP $$$

Given that they are up for an fda decision in Aug, I'm a guessing they will ask
for a 180 day extension because of the potential for approval.

And the expectation of the share price climbing back over a $ before Aug because
of the markets anticipation of its potential approval..

The current 'deadline' is sometime in Feb if my memory serves me correctly. Aug
would be at the end of an extension if granted.

If they had nothing going on, no good reason to justify/anticipate a move up in the
share price, then getting an extension might be a bit tougher to expect. Without
anticipating a r/split to make it happen.

This, I am sure it’ll not be to your liking!
But you asked for my opinions, so here it is,
I don’t think of the list/delist scenario often mentioned on this board.
It will not change the forward looking potential for tnxp.
What difference does it make where it trades.
Holding tnxp for reasons that will not change, regardless where it trades.
It’s the same on RS, what matters is the market cap.
Acquisitions are not based on the numbers of outstanding shares, it’s on forward valuation.
You don’t find acquisitions of companies expected to forward lose money.
Good luck.

Do you happen to know if the stock will be delisted or buyback? anything

20 dma crossed over the 150 dma
Looking @ 1 year 1 day chart.
Next will be the 50 dma to cross over, give it a week or 2!

Nothing changed as far as tnxp, the income impact of fibromyalgia new non-opioid medicine is substantial.
Patience.

This product is for fast approval for FDA, this is not without a raison!!!

Hate to say it, but when it comes to the fda and drug companies,
its pretty apparent the drug industry has more power than folks
realize.

And in this case, as mentioned, it will be interesting to see what
the labeling says with respect to 'who' can use it, and for 'what'
conditions.

Or as I tell those I chat with about drug developments.. There is some
that are getting approved that make you wonder how many were bought
off to get it approved.

dumb&dumber, so what is the conclusion??

Time to be careful flipping. This could take off at anytime.

No, you go figure what the truth is. Just ask ChatGPT or MSFT Copilot, or some other Ai program to get some real answers to your misled beliefs. Dude you are waaay off base with your ideas.

Looked into it a bit more, the Study leading to the FDA, highlighted some concerns earlier this year & noted again in today’s news article.
I am surprised they claim it to be for moderate & severe acute pain. The severe acute part is,
Wholesale acquisition cost for VX-548, is $15.50 per 50 mg tablet, implying daily cost of $31. In a pivotal study, VX-548 helped patients with acute pain after surgery but did not show superiority to opioids, raising concerns about its widespread use. The drug reduced pain more than a placebo in the first 48 hours after surgery, but secondary analysis showed no better results than opioids. Analysts, such as Brian Abrahams from RBC Capital Markets, view the drug's effects as modest, potentially limiting its use to niche markets. Paul Matteis from Stifel noted the drug’s efficacy could complicate prescribing decisions in acute settings. VX-548 was studied in patients after tummy tuck or bunion surgery and for chronic nerve pain caused by diabetes.

You’re right.
Pre December 17th chart is history, for the reason you noted.
Looking forward, from Dec 17th.

When TNXP announced they submitted and then the fda accepted their submission?

The chart that was BASED on what WAS?? The conditions that helped shape
the chart before these fundamental changing events?? That just reshaped
the companies prospects and the way the market will NOW look at the company?
To me, the chart prior to the fda acceptance and announcement of the PDUFA date??
No longer matters to me..

Now I am focused on the 'new' chart cause it will start to reflect the new conditions,and
what the market thinks about the company NOW.

Thats why I use/rely on a much shorter timeframe, and my 'chart' for TNXP starts when
the fda announced it accepted the submission and gave a PDUFA date. Could care less
what it did before that. Cause again, the dynamics have radically changed.

And I do this for all of my trades be it short term or long term.. Only focus on what
IS happening..

disclaimer: in this for the long haul... with $3 as my first goal, adjusting it as the
conditions justify.. (conservative market cap based on existing share count)

Didn't say this was 'designed' as a fibro treatment.

But its designed for short term 'acute' pain. Unless the labeling
curtails its usage, who's to say it won't be tried by a community desperate
for something that helps alleviate a symptom of fibro.

Why I said, wonder what the labeling will say with respect to its 'scope' of application/usage.

Sheesh..

For short term trade, the reason you’re using SHORT moving average!
4long, uses the 1 year daily increment chart.
Not interested in short term trades.
So far, it’s good.
I can’t say the same for day traders.

Vertex has nothing to do with Fibromyalgia.
In case you’re wondering.
Current fibromyalgia drugs are not just ordinary pain killers.

You day traders think you’ve got it all figured out!
Research “timing the market Vs time in the market”.
Timing the market, you’ll get flipped by the time it’s all over.

The answer is NO.
Read the detailed article on Bloomberg.

Is this the easiest play ever....  short all day and cover after hours day after day after day.... 

Let's see what tomorrow brings! 

👀 on that reversal!  

Uh Oh: see the news out on VRTXs fda approval for a
PAIN RELIEF medication??
Question is, if someone with Fibro suffering from PAIN?? Is this now an
option for them? Have to figure out the 'scope' of WHO can take this as a result
of moderate to severe acute pain.. Have to see what their LABEL if anything, limits
who can use this..
Note, its for those suffering from SHORT TERM moderate to severe pain...
Wonder what the definition of SHORT TERM 'is'??

https://finance.yahoo.com/news/vertex-announces-fda-approval-journavx-232500232.html

The U.S. Food and Drug Administration approved twice-daily JOURNAVX for the treatment of adults with moderate-to-severe acute pain. Vertex has established a wholesale acquisition cost for JOURNAVX in the United States of $15.50 per 50mg pill.

Vertex is also evaluating suzetrigine in peripheral neuropathic pain (PNP). The company’s Phase 3 pivotal program for suzetrigine in patients with painful diabetic peripheral neuropathy is ongoing, and Vertex plans to advance its pivotal program evaluating suzetrigine in patients with painful lumbosacral radiculopathy pending discussions with regulators.

Moon: LOL that its 'low class' to tell folks how much you made.

Just think, if you had bought and held at 19 cents, you would be up nearly 100%..
You getting that flipping shares and you are doing something...

Can tell you, given the number of shares I hold? I would be very hesitant to try 'flipping'
that many on a frequent basis hoping to score something vs poor timing costing me..
and making me hesitate to commit that much capital.
(PS: this is from experience doing some flipping)

It's low class to tell people how much money you make. But initial but price was .19 when I started with this pos

I use as mentioned before a SHORT moving average. At 36 cents, its sitting right
on this MA line.

Unfortunately, given the 'negative momentum of the last 3 days, won't be surprised if it
dips below the MA line (MA line went 'neutral' today, lost its positive slope) and has to
wrestle its way back over it Pattern looks similar to what took place when it peaked
back in mid-Dec before it then ran down for almost a month.

Have to remember, we are still 7 months out from Aug. So it has time to be jerked
around for the next few plus months barring any news from the company itself to renew
interest..

Whats wrong, the TRUTH hurts?? Go figure...

20 dma is about to cross over the 150 dma.
Next is the 50 dma (less than 0.03 away), which is sloping upward.
The 100 dma is finally moving upward.
RSI was overbought from 9 up days, now @ 56.8
After mid December spike (RSI 94), RSI had drop, before it took off again.
Looking @ 1 year 1 day chart.

Please stop with your political misinformation (I'll be polite about it). It doesn't do us any good here, or anywhere.

disregard:

Moonie

just how much have you made 'roughly' flipping your shares?

And tell us what your first buy was in the total number of shares you had
and at what price you bought them..

Just curious

Share price vs its moving average line

One thing I pay attention to is and why I advocate/hope for a 'slow and steady'
movement in the share price vs rapid/chaotic. Is the relationship between its MA
and the SP.
7 days ago, this shot up in price, and for the next 5 days, it ran 'up'. Peaked out
at around 47 cents with the MZ line around 35. One heck of a gap. And an observation
of mine is, when that kind of 'gap' develops, the SP & MA line get 'lonely' for
each other. They want to 'find' each other and the expectation goes like this:
-if they stay 'close/tight' to each other during a move up (nice and slow),
they may pause, but the pullback isn't as dramatic when
-they get far apart like they just did. Makes it easy for the share price to be
dropped back down to the MA line like it did this morn.

Just did an update and the MA line is around 36 to 37 cents, and the share price
just nibbled on 36.12..

Called recognizing the PATTERNS and BEHAVIORS
seen in the charts, that are REPEATABLE because its
the masses called investors, their psychology that create
these patterns. And we as humans, for most of us, tend to
think in patterns, never consider 'varying' what we do, how we
think. Function like predictable 'robots'... So those that think
outside of the box?? Can take advantage of this awareness (smile)

Looks like we are heading into the slow bleed stage with a series of lower highs. Can make a little flipping pre market when it spikes up a few cents like it did over and over again a few weeks ago on the way down to 21. Just my opinion.

Naked shorting:

mentioned it before, its common, wall street is doing it
its being done blatantly cause there is very little enforcement
and the reward vs penalties make it worthwhile.

Biggest problem is, the ones caught don't go to jail.

Listening to the Kash Patel fiasco this morning? One of the
questions I didn't hear him asked was, will those behind the
J6 hoax, those that abused their power to persecute the J6ers,
the ones that killed Ashli Babbit and beat the other lady to death..

Face prosecution and an appropriate jail sentence.

Yep, the biggest problem we have is we have laws, regs, but 'select'
accountability if any at all.

They aren't ALL dilution scams.

Yes, there are many that have no chance of success, but end up
lining the pockets of those 'runing things'. Create a lot of 'losers' in the
process (venture capitalists, investors)

But anyone that invests in a company before the PH 2s CONFIRMS that
it has a chance of being successful is placing a VERY risky bet. And anyone
that invests in something that didn't confirm with its PH2, before its Ph 3 does is
playing Russian roulette.

But you try to find a baby bio that goes thru the clinical trial process that
didn't have to DILUTE to raise cash, and you will be lucky to find 'some'. For it
is an expensive process, and DILUTION is likely the only viable option beyond
'loans/venture capital' they have to raise money.

And reverse splits? Far too common and the primary reason why I avoid
investing before the end of the PH 2 at the earliest. Call them an EVIL necessity...
And if they announce a major one, and with no revenue generation in the near future?
You have to expect the share price is going 'down'

So to call a company a 'scam' just cause they do a r/split or dilute is actually libelous
isn't it. Unless you can prove it is scam rather than just part of the normal baby bio
development process. Disagree??

89 millions
By the 2 reasons noted in #10678, that all short volume is naked short, unless there are certain brokerages allowing penny stocks on margin!
Can’t imagine that level of stupidity, going margin on penny stocks. Risk/reward ratio is too large & a 20% move up will trigger position liquidation by the brokerage.

So at this point, how many shares are being shorted?

BB

According to MSFT Copilot, if your tnxp shares are paid for in full (cash account) then your brokerage is not allowed to lend them.
If your position is on margin, your brokerage account contract gives the broker the right to lend, you have no choice in the matter.
Tnxp current share price doesn’t qualify for a margin trade.
So, all shorts are naked shorts.
Checked & confirmed with Schwab.
Too many brokerages are in violation of the SEC, judging by the volume of short interest.

This may be your last chance to lower the PMC… but hey, if you’re selling…

They are all dillution scams is all I've ever seen from any of them that I've ever traded.